Theratechnologies (NASDAQ:THTX - Get Free Report) released its earnings results on Wednesday. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.14), Zacks reports. The company had revenue of $25.00 million for the quarter, compared to the consensus estimate of $31.73 million.
Theratechnologies Stock Up 1.9 %
Shares of THTX traded up $0.03 during trading hours on Friday, reaching $1.65. 71,740 shares of the company traded hands, compared to its average volume of 117,445. The company's fifty day moving average price is $1.74 and its two-hundred day moving average price is $1.45. The company has a market capitalization of $75.87 million, a price-to-earnings ratio of -16.50 and a beta of 1.26. Theratechnologies has a 12 month low of $1.08 and a 12 month high of $2.18.
Institutional Investors Weigh In On Theratechnologies
An institutional investor recently raised its position in Theratechnologies stock. Bank of America Corp DE grew its stake in shares of Theratechnologies Inc. (NASDAQ:THTX - Free Report) by 1,416.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,487 shares of the company's stock after purchasing an additional 15,400 shares during the period. Bank of America Corp DE's holdings in Theratechnologies were worth $30,000 as of its most recent SEC filing.
Wall Street Analyst Weigh In
Separately, Research Capitl raised shares of Theratechnologies to a "strong-buy" rating in a report on Friday, February 14th.
View Our Latest Analysis on THTX
Theratechnologies Company Profile
(
Get Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Featured Stories
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
